Chronic lithium chloride treatment has variable effects on motor behaviour and survival of mice transgenic for the Huntington's disease mutation

Brain Research Bulletin

Volumn 61, Issue 4, 2003, Pages 375-383

  Wood, Nigel I ^a   Morton, A Jennifer ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Drug treatment; LiCl; Neurodegenerative disease; R6 2 mice; Rotarod

Indexed keywords

ANTIDEPRESSANT AGENT; LITHIUM CHLORIDE;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE COURSE; GENE MUTATION; HUNTINGTON CHOREA; LOCOMOTION; MOTOR PERFORMANCE; MOUSE; NEUROPROTECTION; NONHUMAN; ONSET AGE; PHENOTYPE; PRESYNAPTIC NERVE; PRIORITY JOURNAL; SURVIVAL RATE; TRANSGENIC MOUSE; WEIGHT REDUCTION;

EID: 0042666901     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0361-9230(03)00141-2     Document Type: Article

References (31)

1. Atack J.R. Inositol monophosphatase, the putative therapeutic target for lithium. Brain Res. Brain Res. Rev. 22:1996;183-190.
2. Baptista T., Tenend L., Contreras Q., Alastre T., Burguera J.L., de Baptista E.et al. Lithium and body weight gain. Pharmacopsychiatry. 28:1995;35-44.
3. Berridge M.J. Phosphoinositides and signal transduction. Rev. Clin. Basic Pharm. 5(S):1985;5S-13S.
4. Carmichael J., Sugars K.L., Bao Y.P., Rubinsztein D.C. GSK-3β inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation. J. Biol. Chem. 277:2002;33791-33798.
5. Carter R.J., Hunt M.J., Morton A.J. Environmental stimulation increases survival in mice transgenic for exon 1 of the Huntington's disease gene. Mov. Disord. 15:2000;925-937.
6. Carter R.J., Lione L.A., Humby T., Mangiarini L., Mahal A., Bates G.P., Dunnett S.B., Morton A.J. Characterisation of progressive motor deficits in mice transgenic for the human Huntington's Disease mutation. J. Neurosci. 18:1999;3248-3257.
7. Chen D.F., Schneider G.E., Martinou J.C., Tonegava S. Bcl-2 promotes regeneration of severed axons in mammalian CNS. Nature. 385:1997;434-439.
8. Chen G., Zeng W.Z., Yuan P.X., Huang L.D., Jiang Y.M., Zhao Z.H., Manji H.K. The mood-stabilising agents lithium and valproate robustly increase the levels of the neuroprotective protein Bcl-2 in the CNS. J. Neurochem. 72:1999;879-882.
9. Coyle J.T., Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science. 262:1993;689-695.
10. Dixon J.F., Hokin L.E. Lithium acutely inhibits and chronically up-regulates and stabilises glutamate uptake by presynaptic nerve endings in mouse cerebral cortex. Proc. Natl. Acad. Sci. U.S.A. 95:1998;8363-8368.
11. Dixon J.F., Los G.V., Hokin L.E. Lithium stimulates glutamate "release" and inositol 1,4,5-triphosphate accumulation via accumulation of the N-methyl-D-aspartate receptor in monkey and mouse cerebral cortex slices. Proc. Natl. Acad. Sci. U.S.A. 91:1994;8358-8362.
12. F.K. Goodwin, K.R. Jamison (Eds.), Manic-Depressive Illness, Oxford University Press, New York, 1990.
13. Hestbech J., Hansen H., Amdisen A., Olsen S. Chronic renal lesions following long-term treatment with lithium. Kidney Int. 12:1977;205-213.
14. R.H. Lenox, H.K. Manji, Lithium, in: A.F. Shatzberg, C.B. Nemeroff (Eds.), American Psychiatric Press Textbook of Psychopharmacology, American Psychiatric Press, Washington, DC, 1998, pp. 379-429.
15. Lione L.A., Carter R.J., Hunt M.J., Bates G.P., Morton A.J., Dunnett S.B. Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation. J. Neurosci. 19:1999;10428-10437.
16. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 87:1996;493-506.
17. Manji H.K., Moore G.J., Chen G. Lithium up-regulates the cytoprotective protein Bcl-2 in the CNS in vivo: a role for neurotrophic and neuroprotective effects in manic depressive illness. J. Clin. Psychiatry. 61:2001;82-96.
18. McCann M.J., Verbalis J.G., Stricker E.M. LiCl and CCK inhibit gastric emptying and feeding and stimulate OT secretion in rats. Am. J. Physiol. (Regul. Integr. Comp. Physiol. 25). 256:1989;R463-R468.
19. Mindham R.H.S., Steele C., Folstein M.F., Lucas J. A comparison of the frequency of major affective disorder in Huntington's disease and Alzheimer's disease. J. Neurol. Neurosurg. Psychol. 48:1985;1172-1174.
20. Miodownik C., Witztum E., Lerner V. Lithium-induced tremor treated with vitamin B6: a preliminary case series. Int. J. Psychiatry Med. 32:2002;103-108.
21. Nonaka S., Chuang D.-M. Neuroprotective effects of chronic lithium on focal cerebral ischaemia in rats. Neuroreport. 9:1998;2081-2084.
22. Nonaka S., Hough C.J., Chuang D.-M. Chronic lithium treatment robustly protects neurones in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx. Proc. Natl. Acad. Sci. U.S.A. 95:1998;2642-2647.
23. Ona V.O., Li M., Vonsattel J.P.G., Andrews L.J., Khan S.Q., Chung W.M., Frey A.S., Menon A.S., Li X.-J., Stieg P.E., Yuan J., Penney J.B., Young A.B., Cha J.-H.J., Friedlander R.M. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature. 399:1999;263-267.
24. Rinaman L. A functional role for central glucagon-like peptide-1 receptors in lithium chloride-induced anorexia. Am. J. Physiol. (Regul. Integr. Comp. Physiol. 46). 227:1999;R1537-R1540.
25. Sathasivam K., Hobbs C., Mangiarini L., Mahal A., Turmaine M., Doherty P., Davies S.W., Bates G.P. Transgenic models of Huntington's disease. Philos. Trans. R. Soc. Lond. B. 354:1999;963-969.
26. Savvopoulos S., Golaz J., Bouras C., Constantinidis J., Tissot R. Huntington chorea. Anatomoclinical and genetic study of 17 cases. Encephale. 16:1990;251-259.
27. Tremont G., Stern R.A. Minimizing the cognitive effects of lithium therapy and electroconvulsive therapy using thyroid hormone. Int. J. Neuropsychopharmacol. 3:2000;175-186.
28. Turmaine M., Raza A., Mahal A., Mangiarini L., Bates G.P., Davies S.W. Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. PNAS. 97:1999;8093-8097.
29. Vonsattel J.P., DiFiglia M. Huntington disease. J. Neuropathol. Exp. Neurol. 57:1998;369-384.
30. Wei H., Leeds P.R., Qian Y., Wei W., Chen R., Chuang D. Beta-amyloid peptide-induced death of PC12 cells and cerebeller granule cell neurones is inhibited by long-term lithium treatment. Eur. J. Pharmacol. 392:2000;117-123.
31. Wei H., Qin Z.-H., Senatorov V.V., Wei W., Wang Y., Qian Y., Chuang D. Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington's disease. Neuroscience. 106:2001;603-612.